Merck Animal Health Announces USDA Approval of INNOVAX® ND-IBD-ILT

August 12, 2026

First recombinant vaccine to help protect against four major poultry diseases in a single hatchery vaccination

RAHWAY, N.J., Aug. 13, 2026 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced U.S. Department of Agriculture approval of INNOVAX® ND-IBD-ILT, the first recombinant vaccine to provide protection against Newcastle disease, infectious bursal disease, infectious laryngotracheitis and Marek’s disease in a single hatchery vaccination.

INNOVAX ND-IBD-ILT is designed to help poultry veterinarians streamline vaccination programs and simplify flock health management by establishing broad immunity early against four major poultry diseases in a single hatchery administration.

The vaccine provides protection throughout the production cycle, helping support consistent flock health and performance.

Poultry producers continue to face increasing pressure to optimize flock health while managing labor and operational demands. INNOVAX ND-IBD-ILT is designed to help simplify vaccination programs while supporting early, broad disease protection, and making flock management more efficient.

“Poultry producers and veterinarians need disease protection that is both comprehensive and practical,” said Charles Broussard, D.V.M., senior account manager for poultry sales, Merck Animal Health. “By helping protect against four major diseases in a single hatchery vaccination, INNOVAX ND-IBD-ILT reduces complexity and provides veterinarians with greater convenience throughout the production cycle.”

INNOVAX ND-IBD-ILT incorporates dual glycoprotein inserts designed to provide strong and consistent infectious laryngotracheitis protection while simplifying vaccination strategies. By concentrating vaccination efforts at the hatchery, the vaccine can reduce bird handling, optimize labor and reduce operational complexity.

INNOVAX ND-IBD-ILT will be commercially available in the fourth quarter of 2026. For more information about INNOVAX ND-IBD-ILT, contact your Merck Animal Health representative or visit https://www.merck-animal-health-usa.com/hub/innovax/.

Product Label

Merck Animal Health announces USDA approval of INNOVAX® ND-IBD-ILT, a category-first recombinant vaccine designed to help poultry producers and veterinarians simplify flock health management with expanded protection against four major diseases in a single hatchery vaccination.

About Merck Animal Health

Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is a global animal health business committed to The Science of Healthier Animals™. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).